For example, ~50% of the AML patients with t (5, 6) (q22; q22) RUNX1-RUNX1T1 have a favorable prognosis according to ELN risk stratification but show poor prognosis after intensive chemotherapy (7). This evidence concerns the gene RUNX1 and acute myeloid leukemia.